Johnson & Johnson: What we know about the single dose vaccine that has been suspended


03:34 PM

Tuesday 13 April 2021

I wrote – Rana Osama:

In a new blow to the Corona virus vaccines, the US Food and Drug Administration (FDA) recommended that “Johnson & Johnson” be suspended, as a precaution, on suspicion of causing clots like the British “AstraZeneca”.

About 7 million Americans have received the Johnson & Johnson vaccine so far, according to the US Centers for Disease Control and Prevention. Among them, 129 people reported side effects severe enough to go to the emergency room or see a doctor.

Earlier, the (FDA) reported that it had not yet revealed a causal link between “Johnson & Johnson” and blood clots, but the European Medicines Agency announced that it was studying cases of blood clots in Europe after receiving the American vaccine.

The “New York Times” newspaper quoted US officials, that 6 cases of blood clots were detected after they were vaccinated with “Johnson & Johnson”, in women between the ages of 18 and 48 years, one of whom died, and the other was transferred to hospital in critical condition.

Here is the most important information about the Johnson & Johnson vaccine:

The first vaccine to be used in a single dose.

– Developed by the Belgian company, “Jansen”, a subsidiary of “Johnson & Johnson” of America.

It is easy to store and can be stored in the regular refrigerator.

It depends on the adenovirus vectors (which are viruses that have been altered so that they cannot make you sick or reproduce).

It was approved by the European Medicines Agency on March 11th, to become the fourth vaccine approved in the European Union, which includes 27 countries.

The World Health Organization gave him the green light for urgent use on March 12th.

– World Health has included it within the Kovacs program for the distribution of vaccines in the world to middle and poor countries.

Its effectiveness has reached 85% against acute symptoms of Covid 19, and 100% in preventing death, according to the World Health Organization.

It showed efficacy against severe cases by 81.7 percent in South Africa and 87.6 percent in Brazil.

Tested on 44K in the US, South Africa and Latin America.

It showed efficacy against the British and South African versions of the corona mutated.

The first dose of it is supposed to be delivered to Europe from April 19.

Side effects include: pain at the injection site, redness, slight fever for a day or two after the injection, muscle pain, and mild headache.


Please enter your comment!
Please enter your name here